Immix Biopharma
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 month.
- Its last 5 Sell calls were actually followed by a +11% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is +13.0% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 13.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -55.0% | Better than 9% |
| Return on invested capital | -54.7% | Better than 5% |
Momentum C
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -49.0% | Better than 6% |
| 6-month return | -20.7% | Better than 26% |
| 12-month return (ex latest month) | 88.2% | Better than 94% |
| Distance below 52-week high | 53.9% | Better than 15% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 10.0x | Better than 93% |
| Debt to assets | 1.0% | Better than 93% |
| Interest coverage | -16,537.1x | Better than 0% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 264.9% | Better than 97% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.04
- Open
- 7.00
- Day range
- 6.90 - 7.50
- Avg price
- 7.11
- Volume
- 1.57M
- Turnover
- 11.19M
- Turnover ratei
- 2.30%
- Volume ratioi
- 1.56
- Amplitudei
- 8.52%
- 52-week rangei
- 3.78 - 15.10
Valuation
- P/Ei
- -7.82
- P/E (TTM)i
- -8.39
- P/Bi
- 1.74
- EPSi
- -0.89
- Book value / shi
- 4.00
- Net profit
- -74.59M
- Net assets
- 335.08M
Share structure
- Market cap
- 583.33M
- Float capi
- 476.30M
- Shares out
- 83.81M
- Float sharesi
- 68.43M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2021-12-16
53.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+1.32M net over the window
Short interest
- Shares short
- 11.25M
- % of floati
- 13.55%
- Days to coveri
- 9.24
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Immix Biopharma (IMMX)?
Immix Biopharma last traded at 6.96. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Immix Biopharma's market cap?
About 583.33M.
What is the P/E ratio of Immix Biopharma?
The trailing twelve-month P/E is -8.39. The Valuation tab shows it against the stock's own five-year range.
Does Immix Biopharma pay a dividend?
Immix Biopharma does not currently pay a regular dividend.
Is Immix Biopharma a buy according to analysts?
The consensus of 5 analysts is a Buy rating, with an average 12-month price target of 25.40, which implies 264.9% upside from the current price. This is not investment advice.
What is Immix Biopharma's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Immix Biopharma a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Immix Biopharma discussion 0 comments